Pfizer and Tempus collaborate to develop cancer drugs

Multinational pharmaceutical and biotechnology company Pfizer and AI data company Tempus have announced a multi-year strategic alliance to use AI and machine learning to inform oncology drug discovery and development.

Pfizer will use the Tempus de-identified data library to accelerate the development of therapeutics in oncology. It will also use Tempus’s companion AI-based diagnostic offerings and clinical trial matching program to support therapeutic research and development.

“Pfizer shares our commitment to bringing new therapies to patients faster, and we look forward to working together to unlock the next generation of oncology therapeutics,” Eric Lefkofsky, founder and CEO of Tempus, said in a statement.

“This is Tempus’ third strategic collaboration with a global pharmaceutical leader in the past year, as we believe that combining our technological capabilities with our deep expertise in pharmaceutical research and development will bring us significantly closer to realizing the full potential of precision medicine.”

BIG TREND

This is not the first time Tempus has partnered with pharmaceutical giants in the field of cancer treatment.

Last year the company announced a three-year agreement with British multinational pharmaceutical and biotechnology company GSK, which included an initial payment of US$70 million to accelerate drug development in oncology, identify targeted drugs, improve clinical trial design and accelerate trial registration.

The Chicago company announced a collaboration with American pharmaceutical company Eli Lilly to expand access to genomic testing for patients with advanced/metastatic non-small cell lung cancer.

In 2021 Tempus announced a strategic collaboration with British-Swedish multinational pharmaceutical and biotech company AstraZeneca to advance drug discovery and development in oncology.

The company announced last year that received $275 million in debt and equity financing from existing investors, bringing the total funds raised to $1.3 billion.

Other players using AI for oncology drug discovery include Artificial intelligence pathology company PathAI and tech company Exscientia.

Content Source

Dallas Press News – Latest News:
Dallas Local News || Fort Worth Local News | Texas State News || Crime and Safety News || National news || Business News || Health News

Related Articles

Back to top button